Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

Extreme Language Ultra-High Potency
The newest generation of small-molecule therapies bring containment needs well beyond those of conventional HPAPIs. What does this mean for the pharma lexicon – and the pharma landscape? read more
Horizon Lines: A Quarterly Review of NDAs – October- December 2025
This quarterly review of New Drug Applications contains data for applications approved for the first time during the last quarter of 2025, which includes New Molecular Entities (NMEs) and new biologics. A total of 40 applications were approved by the FDA during these three months. read more
Quality: The Gold Standard for CDMOs - No Exceptions, No Compromises
In today’s hyper-competitive pharmaceutical landscape, innovation, speed-to-market and cost control usually take the spotlight when selecting a contract development and manufacturing organization (CDMO). However, underneath all those metrics, a single truth remains: if quality fails, so does everything else. read more
Why DSCSA Compliance in 2026 Hinges on Execution, Not Implementation
After a decade of ramp-up, the era of DSCSA enforcement is no longer theoretical — it’s here. But as we move deeper into this phase of full compliance, the real story unfolds not just in establishing data feeds, but in the operational cracks that persist behind the scenes. read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Scinai Finalizes Corporate Reorganization, Separates CDMO and R&D Operations
Thursday, April 09, 2026
Scinai Immunotherapeutics has completed a strategic corporate reorganization that establishes a dedicated contract development and manufacturing ... read more
Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
Thursday, April 09, 2026
Altruist Biologics, an Innovent Biologics subsidiary and contract development and manufacturing organization (CDMO), announced that its Hangzhou ... read more
Ofichem Consolidates Brands Under Unified CDMO Identity
Thursday, April 09, 2026
Ofichem has unified its business divisions under a single brand identity, announcing that all operations will now trade under the Ofichem name. The ... read more
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
Tuesday, April 07, 2026
Azenta announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead ... read more
Perceptive Discovery Expands In Vitro Capabilities at Needham, MA Site to Accelerate Preclinical Oncology Research
Friday, April 03, 2026
Perceptive Discovery announced a major expansion of its in vitro laboratory capabilities at its Needham, Massachusetts facility. This strategic ... read more